To treat patients with hepatoblastoma appropriately, they are risk stratified using age, alpha fetoprotein (AFP) levels, the extent of liver segment and blood vessel involvement, and the presence of metastatic disease (2, 3). This evidence concerns the gene AFP and metastatic neoplasm.